HeartSciences (HSCS) to Release Earnings on Thursday

HeartSciences (NASDAQ:HSCS) is expected to be announcing its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings results on Monday, December 15th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.05. The company had revenue of $2.42 million for the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect HeartSciences to post $-10 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

HeartSciences Price Performance

NASDAQ:HSCS opened at $2.62 on Thursday. The company has a market cap of $8.33 million, a P/E ratio of -0.38 and a beta of 2.53. The firm’s 50 day moving average is $3.07 and its two-hundred day moving average is $3.11. HeartSciences has a fifty-two week low of $2.01 and a fifty-two week high of $6.47.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Ascendiant Capital Markets upped their price objective on HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a report on Monday, December 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, HeartSciences currently has an average rating of “Hold” and a consensus target price of $9.20.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in HeartSciences stock. Geode Capital Management LLC bought a new position in HeartSciences Inc. (NASDAQ:HSCS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences at the end of the most recent reporting period. 17.24% of the stock is currently owned by institutional investors.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.